LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing and currently employs 573 full-time employees. The company went IPO on 2021-07-30. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
LakeShore Biopharma Co Ltd의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
LakeShore Biopharma Co Ltd 주요 수익원은 Biopharmaceutical Products이며, 최신 수익 발표에서 수익은 85,194,300입니다. 지역별로는 China이 LakeShore Biopharma Co Ltd의 주요 시장이며, 수익은 85,194,300입니다.
LakeShore Biopharma Co Ltd은 수익성이 있나요?
no, 최신 재무제표에 따르면 LakeShore Biopharma Co Ltd의 순손실은 $-99입니다.